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Research article
Ερευνητικό άρθρο
ABSTRACT: The focus of this study was to evaluate the efficacy of ceftiofur+gentamicin combination to increase 
the success of antimicrobial inhibition against resistant Escherichia coli (E.coli) strains isolated from animals. Interac-
tion between drugs was determined using checkerboard method and the fractional inhibitory concentration index was 
interpreted as synergism, antagonism and indifference. The combination was defined as bactericidal or bacteriostatic 
based on the minimum bactericidal test results. Mutant prevention concentration test was used to evaluate the resis-
tance tendency suppression potential of the combination. The synergistic effect was detected for all E. coli strains by 
the checkerboard method; even the strains that were resistant to the individual compounds in the combination. Based 
on the results of minimum bactericidal concentration test, the combination exhibited bactericidal effect against all E. 
coli strains. In addition, the individual mutant prevention concentrations of ceftiofur and gentamicin decreased up to 
125-fold by using the combination for the inhibition of resistant E. coli strains. The results indicated that killing poten-
tial of co-use of the compounds is much stronger than their individual use. The combination achieved to decrease the 
mutant prevention concentrations and this can reduce the risk of emergence of single mutations during treatment done 
with suggested doses.
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INTRODUCTION
As a member of the intestinal microbiota, Esche-richia coli (E. coli) is responsible for many in-
testinal or extraintestinal opportunistic infections in 
humans and animals (Hopkins et al., 2005; Ingerson 
Mahar and Reid, 2011). Due to the lack of effective 
therapeutic options in the veterinary field, the treat-
ment of infections caused by resistant E. coli is a ma-
jor concern. Resistance gene-based dose optimization 
is one pragmatic approach to combat resistant bacte-
ria. However, resistance gene variability is a limiting 
factor affecting the success of treatment (Cengiz et al., 
2013). Antimicrobial combinations should be consid-
ered for the treatment of infections caused by various 
resistance gene-containing strains. Combination ther-
apy involves the co-use of two or more compounds 
with synergistic interactions and increases the treat-
ment potential of the infection provided that the com-
bination does not lead to increased toxicity (Sun et al., 
2016; Tamma et al., 2012). The synergistic activity of 
β-lactam plus aminoglycoside has been widely inves-
tigated against many infectious agents (Tamma et al., 
2012). β-lactams inhibit peptidoglycan biosynthesis, 
disrupting bacterial cell wall synthesis and increas-
ing the influx of aminoglycoside to block ribosomal 
protein synthesis (Kohanski et al., 2010). Ceftiofur 
(CEF) is a semi-synthetic member of third generation 
cephalosporins and is resistant to several β-lactamas-
es (Meegan, 2013). As an aminoglycoside, gentami-
cin (GEN) inhibits protein synthesis by binding to the 
bacterial 30S ribosomal subunit. Based on the results 
of recent studies, β-lactam+aminoglycoside remains 
an effective therapeutic option for the treatment of 
critical clinical cases (Theelen, 2019). The aim of this 
study was to determine the efficacy and resistance 
prevention potential of CEF+GEN as a novel β-lac-
tam+aminoglycoside combination. Therefore, the in-
teraction between CEF and GEN was determined, and 
the bactericidal characteristics of the combination and 
its resistance tendency toward E. coli strains under the 
combination pressure were evaluated.
MATERIAL AND METHODS
For isolation of E. coli, samples collected from 
cattle were directly spread onto Eosine Methylen Blue 
Agar-Levine and MacConkey Agar, and incubated 
under aerobic conditions. Candidate E. coli colonies 
were identified by API 20 E, and results were evalu-
ated by API-Web system. Broth microdilution testing 
was performed to determine the minimum inhibitory 
concentrations (MICs) of the antimicrobials accord-
ing to the guidelines of Clinical Laboratory Standards 
Institute (CLSI, 2016). Antimicrobials were obtained 
as an analytical standard powder (Fluka). MICs were 
defined as the minimum concentration of antibiot-
ic that inhibited growth of the organism. PCR and 
qRT-PCR were used to characterize the presence and 
expression levels of molecular mechanisms of the 
resistance as described previously (Sahinturk et al., 
2016). Briefly, gyrA, parC and oqxB genes were PCR 
amplified using specific primers and PCR products of 
gyrA and parC were sequenced. qRT-PCR was used 
to determine expression level of marA, acrB, soxS 
and ompF genes. E. coli AG100 was used as a con-
trol strain. Overexpression was defined as a 1.5-fold 
increase in the genes. 
Six E. coli isolates with various resistance deter-
minants and profiles were used in this study (Table 
1). E. coli E245 was resistant to both CEF and GEN, 
and E. coli E246 was resistant to GEN only. The 4/6 
of E. coli strains were susceptible to CEF and GEN. 
In this study, the efficacy of the combination was test-
ed against E. coli strains resistant to compounds in 
the combination and the resistance preventive poten-
tial of the combination was evaluated against all E. 
coli strains. The interaction between drugs was deter-
mined by the checkerboard test. The fractional inhibi-
tory concentration indexes (FICIs) provided from the 
checkerboard test were interpreted as follows: FICI≤ 
0.5 = synergy; FICI > 4.0 = antagonism; and FICI > 
0.5-4 = indifference (Table 1) (Elipoulos and Moeller-
ing, 1996). The minimum bactericidal concentration 
(MBC) and mutant prevention concentration (MPC) 
of the combination were determined as previously de-
scribed (Blondeau et al., 2001; Hansen and Blondeau, 
2005). The MBC was defined as the lowest concen-
tration showing ≥ 99.9 % death compared with the 
initial inoculum. The combination was defined as 
bactericidal and bacteriostatic for MBC:minimum in-
hibitory concentration (MIC) ratios of 1-4 and ≥ 8, re-
spectively (Table 2) (Maaland et al., 2015).  The MPC 
was determined as the concentration that allowed no 
growth of bacteria at the end of the 72-h incubation 
period (Table 2). The inoculum densities used for 
MIC-MBC and MPC determination were 107 cfu/ml 
(equivalent to 0.5 MacFarland turbidity) and 1010 cfu/
ml, respectively. 
RESULTS 
The FICI values of the combination therapy for E. 
coli strains are shown in Table 1. The FICIs of the 
combination ranged from 0.1 to 0.5. A synergistic ef-
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fect was detected for all E. coli strains by the check-
erboard method. Based on the MBC:MIC ratios, the 
combination exhibited bactericidal effect against all 
E. coli strains (Table 2). The MBC:MIC ratio was two 
for oqxB containing-E. coli E306 and one for the rest 
of E. coli strains. The individual MPCs ranged from 
32 µg/ml to 512 µg/ml for CEF and from 16 µg/ml 
to 4096 µg/ml for GEN (Table 2). The MPCs of the 
combination ranged from 0.256 µg/ml to 64 µg/ml. 
The individual MPCs of CEF and GEN decreased by 
up to 128-fold using the combination for the inhibi-
tion of resistant E. coli strains. The MPC:MIC ratio 
of the combination ranged from 2 to 32 for E. coli 
strains. The highest MPC:MIC ratio was detected for 
the most susceptible isolate, E. coli E175. 
Table 1. Resistance profiles and mechanisms of E. coli and checkerboard data with the interpretations






gyrA parC oqxB marA acrB soxS ompF
E175 SMX ↓↓ ↓ ↓↓ ↑





↓↓ ↓↓ ↑↑ ↑








↑ ↑↑ ↑↑ ↑






↑↑ ↑↑ ↑↑↑ ↓↓↓
E269 NAL, SMX, 
TMP, TET, 
OTC, CST
↓↓ ↓ ↑↑ ↑






  + ↓↓ ↓↓ ↑ ↑
a: quinolone resistance determining region
b: plasmid-mediated quinolone resistance
c: compared to AG100; ↑: 1–5 fold increased; ↑ ↑: 5–10 fold increased; ↓: 1–5 fold decreased; ↓↓: 5–10 fold decreased; 
↓↓↓: ≥ 10 fold decreased.
d: SMX: sulfamethoxazole, NAL: nalidixic acid, CIP: ciprofloxacin, SMX: sulfamethoxazole, TMP: trimethoprim, TET: tetracycline, 
OTC: oxytetracycline, CHL: chloramphenicol, ORB: orbifloxacin, GAT: gatifloxacin, AMP: ampicillin, CEF: ceftiofur, ERY: 
erythromycin, CST: colistin
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E175 1 4 0,128/1 0,3 8 4 0.128/1 8 1 1 128 128 4/32 128 32 32
E222 2 4 0,128/1 0,3 8 4 0.128/1 4 1 1 128 128 2/16 64 32 16
E245 16 128 1/16 0,1 64 256 1/16 4 2 1 256 4096 4/64 16 32 4
E246 2 64 0,512/8 0.3 2 64 0.512/8 1 1 1 128 512 1/16 64 8 2
E269 1 4 0,256/1 0,5 1 4 0.256/1 1 1 1 32 32 2/8 32 8 8
E306 4 2 0,512/0,064 0,1 4 2 1/0.128 1 1 2 512 16 2/0.256 128 8 4
a: Synergistic interaction
DISCUSSION
β-lactam-aminoglycoside combinations are 
primarily preferred to expand the spectrum of action 
and have synergistic effects. These combinations have 
been used as an initial therapeutic option since 1984 
(Rafei, 2018). All aminoglycosides can cause varying 
degrees of ototoxicity and nephrotoxicity. Nephrotox-
icity is the most common adverse effect of aminogly-
coside treatment (Prescott et al., 2013). β-lactam-ami-
noglycoside combinations are also considered a less 
toxic therapeutic option in addition to having poten-
tial synergistic and expanded spectrum activities. In 
veterinary medicine, aminoglycosides are most often 
combined with penicillin (EMA, 2017).  Cephalospo-
rins are also synergistic with aminoglycosides for the 
treatment of neutropenic human patients with infec-
tions caused by resistant strains (Prescott et al., 2013; 
Rafei, 2018). Therefore, the focus of this study was 
to compare the efficacy of the individual use of the 
antimicrobials with synergistically acting CEF+GEN 
combination against E. coli strains with resistance to 
many antimicrobials. The results of this study showed 
that CEF+GEN effectively inhibited E. coli strains 
with varying susceptibility profiles and different re-
sistance determinants. Multidrug resistance (MDR) 
is a potential limiting factor in the treatment of in-
fectious bacteria. FICI data showed that the CEF+-
GEN combination could more effectively inhibit E. 
coli strains resistant to compounds in the combination 
and those resistant to many other antimicrobials from 
different groups. The use of a second antimicrobial 
can reduce the risks for patients infected with MDR 
organisms and will provide adequate coverage for po-
tential pathogens causing an infection (Tamma et al., 
2012). In clinical trials, the efficacy of β-lactam-ami-
noglycoside combinations has also been shown. For 
example, the combination of amikacin and ampicil-
lin was found to be suitable for the treatment of foals 
with sepsis (Theelen, 2019). Similarly, the CEF+GEN 
combination can also be used to increase the clinical 
success of treatments for infections caused by E. coli 
strain even when it is resistant to CEF and/or GEN. 
Noel et al. (2018) showed that addition of amikacin 
to ceftalazone/tazobactam bacterial clearance were 
increased and emergence of resistance to ceftala-
zone/tazobactam was prevented. Tschudin-Sutter et 
al. (2018) indicated that combination therapy with 
β-lactam+aminoglycoside might improve mortality 
of Pseudomonas aeruginosa causing blood stream 
infection. Based on the results of previous studies, 
CEF+GEN combination can be preferred without risk 
of emergence of resistance to inhibit various resis-
tance determinant-carrying E. coli strains instead of 
monotherapy with CEF or GEN alone. The results of 
this study showed that the MICs of the CEF+GEN 
combination were equal to their MBCs. Based on the 
MBC:MIC ratio, the combination was defined as bac-
tericidal against all E. coli strains. The co-use of CEF 
and GEN caused a decrease in their individual MBCs 
by up to 64-fold. The MBCs of CEF and GEN were 
below the clinical breakpoint of CEF (S≤8 μg/ml, R>8 
μg/ml) for all E. coli strains and below that of GEN 
(S≤2 μg/ml, R>4 μg/ml) for four E. coli strains. The 
genetic mechanism of resistance can be determinative 
for the bactericidal activity of antimicrobials (Cengiz 
et al., 2013). Therefore, sustaining of bactericidal ac-
tivity of each compound in the combination is crucial 
by decreasing their individual MBCs. The other ben-
efit of the CEF+GEN combination was a change in 
the individual MPCs of CEF and GEN. The MPCs 
decreased for all E. coli strains, and the MPC:MIC 
ratio decreased for four strains. The distance between 
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MPC and MIC is determinative for the emergence of 
resistant sub-populations during antimicrobial ther-
apy (Hansen and Blondeau, 2005). The lowering 
MPC:MIC ratio may reduce the risk of emergence 
of resistance or evolving of resistant strains to high-
ly resistant strains. As a clinical perspective, this im-
provement may increase the success of antimicrobial 
therapy applied by CEF+GEN combination. 
CONCLUSION
In conclusion, the combination decreased the 
MPCs and narrowed the range between the MIC and 
MPC. This improvement can reduce the risk of the 
emergence of single mutations during treatment with 
currently approved doses. In addition, the bactericidal 
effects of the compounds sustained at concentrations 
below the clinical breakpoints of the individual com-
pounds by their use in a combination. This result in-
dicates that the killing potential of the co-use of the 
compounds is much stronger than their individual use. 
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